Karakurt Eryılmaz Melek, Karaağaç Mustafa
Department of Medical Oncology, Hitit University Education and Research Hospital, Çorum, Turkey.
Department of Medical Oncology, School of Medicine, Necmettin Erbakan University, Konya, Turkey.
J Oncol Pharm Pract. 2019 Dec;25(8):2031-2034. doi: 10.1177/1078155218818250.
Abiraterone is an oral inhibitor of cytochrome P450 (17alpha)-hydroxylase/17,20 lyase (CYP17) complex critical to androgen production. Abiraterone in combination with prednisone is currently FDA approved for use in men with metastatic castration-resistant prostate cancer, both in the pre- and post-chemotherapy settings. This article discusses the treatment with abiraterone in a patient with metastatic castration-resistant prostate cancer on hemodialysis.
阿比特龙是一种细胞色素P450（17α）-羟化酶/17,20裂解酶（CYP17）复合物的口服抑制剂，该复合物对雄激素的产生至关重要。阿比特龙联合泼尼松目前已获美国食品药品监督管理局（FDA）批准，可用于转移性去势抵抗性前列腺癌男性患者，包括化疗前和化疗后的情况。本文讨论了一名接受血液透析的转移性去势抵抗性前列腺癌患者使用阿比特龙的治疗情况。
